Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Stage 4 Cardiovascular-Kidney-Metabolic Syndrome: A Propensity Score-Matched Study.

ABSTRACT:

Background

This study investigated the effects of sodium-glucose cotransporter 2 inhibitors (SGLT2is) on patients with stage 4 cardiovascular-kidney-metabolic syndrome over 1 year.

Methods

Data from patients with stage 4 cardiovascular-kidney-metabolic syndrome hospitalized at Civil Aviation General Hospital from March 2021 to September 2023 were collected. Patients were classified into the SGLT2i group and the control group on the basis of SGLT2i exposure. A propensity score-matched model established a well-balanced comparison between the groups. The initial occurrence of major adverse cardiovascular events (MACEs), major adverse kidney events (MAKEs) and all-cause death within 1 year were assessed.

Results

A total of 3657 patients were included, resulting in 812 mat

SUBMITTER: Liu T 

PROVIDER: S-EPMC12748069 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature